Our top pick for
Longeveron Inc is a biotechnology business based in the US. Longeveron shares (LGVN) are listed on the NASDAQ and all prices are listed in US Dollars. Longeveron employs 12 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.98|
|52-week range||$3.20 - $10.00|
|50-day moving average||$3.61|
|200-day moving average||$5.55|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.55|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-11)||15.36%|
|1 month (2021-09-17)||9.94%|
|3 months (2021-07-16)||-36.62%|
|6 months (2021-04-16)||-38.96%|
|1 year (2020-10-14)||N/A|
|2 years (2019-10-14)||N/A|
|3 years (2018-10-14)||N/A|
|5 years (2016-10-14)||N/A|
|Revenue TTM||$3.9 million|
|Gross profit TTM||$1.8 million|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$76.1 million|
TTM: trailing 12 months
There are currently 261,014 Longeveron shares held short by investors – that's known as Longeveron's "short interest". This figure is 14.9% up from 227,167 last month.
There are a few different ways that this level of interest in shorting Longeveron shares can be evaluated.
Longeveron's "short interest ratio" (SIR) is the quantity of Longeveron shares currently shorted divided by the average quantity of Longeveron shares traded daily (recently around 127948.03921569). Longeveron's SIR currently stands at 2.04. In other words for every 100,000 Longeveron shares traded daily on the market, roughly 2040 shares are currently held short.
To gain some more context, you can compare Longeveron's short interest ratio against those of similar companies.
However Longeveron's short interest can also be evaluated against the total number of Longeveron shares, or, against the total number of tradable Longeveron shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Longeveron's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Longeveron shares in existence, roughly 10 shares are currently held short) or 0.0945% of the tradable shares (for every 100,000 tradable Longeveron shares, roughly 95 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Longeveron.
Find out more about how you can short Longeveron stock.
We're not expecting Longeveron to pay a dividend over the next 12 months.
Longeveron's shares were split on a 2:5 basis on 11 March 2008. So if you had owned 5 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Longeveron shares – just the quantity. However, indirectly, the new 150% higher share price could have impacted the market appetite for Longeveron shares which in turn could have impacted Longeveron's share price.
Longeveron Inc. , a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.